George, Goldy C.
Mendoza, Tito R.
Iwuanyanwu, Eucharia C.
Manandhar, Meryna
Afshar, Solmaz F.
Piha-Paul, Sarina A.
Tsimberidou, Apostolia
Naing, Aung
Cleeland, Charles S.
Hong, David S.
Funding for this research was provided by:
Hawn Foundation (na)
Article History
Received: 10 October 2019
Accepted: 11 November 2019
First Online: 25 November 2019
Compliance with ethical standards
:
: GCG declares that she has no conflict of interest. TRM declares that he has no conflict of interest. ECI declares that she has no conflict of interest. MM declares that she has no conflict of interest. SFA declares that she has no conflict of interest. CSC declares that he has no conflict of interest. SAP reports grants from NIH/NCI during the conduct of the study; other from AbbVie, Inc., Aminex Therapeutics, BioMarin Pharmaceutical, Inc., Boehringer Ingelheim, BristolMyers Squib, Cerulean Pharma Inc., Chugai Pharmaceutical Co., Ltd., Curis, Inc., Five Prime Therapeutics, Genmab A/S, GlaxoSmithKline, Helix BioPharma Corp., Incyte Corp., Jacobio Pharmaceuticals Co., Ltd., Medimmune, LLC., Medivation, Inc., Merck Sharp and Dohme Corp., NewLink Genetics Corporation/Blue Link Pharmaceuticals, Novartis Pharmaceuticals, Pieris Pharmaceuticals, Inc., Pfizer, Principia Biopharma, Inc., Puma Biotechnology, Inc., Rapt Therapeutics, Inc., Seattle Genetics, Taiho Oncology, Tesaro, Inc., TransThera Bio, XuanZhu Biopharma, Amphivena Therapeutics, Inc., outside the submitted work. AT reports research funding: IMMATICS, Parker Institute for Cancer Immunotherapy, Tempus, EMD Serono; Baxalta; Foundation Medicine; ONYX; Bayer; Boston Biomedical; Placon Therapeutics; Karus Therapeutics; Tvardi; OBI Pharma. Consulting or Advisory Role: Tempus, Roche, Covance, Genentech. Dr. Naing reports grants from NCI; EMD Serono; MedImmune; Healios Onc. Nutrition; Atterocor; Amplimmune; ARMO BioSciences; Eli Lilly; Karyopharm Therapeutics; Incyte; Novartis; Regeneron; Merck; BMS; Pfizer, CytomX Therapeutics; Neon Therapeutics; Calithera Biosciences; TopAlliance Biosciences; Kymab; PsiOxus; Immune Deficiency Foundation (Spouse), other from CytomX Therapeutics; Novartis, other from ARMO BioSciences, outside the submitted work<b>.</b> DSH reports grants from Bayer, Lilly, Genentech, LOXO, Pfizer, Amgen, Mirati, Ignyta, Merck, Daichii-Sanko, Eisai, Adaptimmune, Abbvie, Astra-Zeneca, BMS, Genmab, Infinity, Kite, Kyowa, Medimmune, Molecular Template, Novartis, Takeda; personal fees from Mirna, LOXO, Bayer, Baxter, Guidepoint global, Oncoresponse, Janssen, Molecular Match, outside the submitted work.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.